Gilead Sciences, Inc. $GILD Shares Sold by First Bank & Trust

Key Points

• First Bank & Trust has reduced its position in Gilead Sciences by 13.1%, now owning 43,836 shares valued at approximately $4.86 million, making it the 18th largest holding in their portfolio.
• Multiple hedge funds have increased their stakes in Gilead, with Vanguard Group raising its position by 1.7% and Price T Rowe Associates growing its stake by 314.6% during the past quarter.
• Gilead Sciences recently reported earnings per share of $2.01 for the last quarter, exceeding expectations, and announced a quarterly dividend of $0.79 per share, symbolizing a 2.8% yield for shareholders.

First Bank & Trust cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,836 shares of the biopharmaceutical company's stock after selling 6,601 shares during the period. Gilead Sciences makes up about 0.9% of First Bank & Trust's holdings, making the stock its 18th biggest position. First Bank & Trust's holdings in Gilead Sciences were worth $4,860,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ariel Investments LLC lifted its position in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC raised its stake in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 109 shares during the period. Swedbank AB increased its position in shares of Gilead Sciences by 0.8% in the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock valued at $237,393,000 after acquiring an additional 16,663 shares during the last quarter. Focus Partners Wealth lifted its position in shares of Gilead Sciences by 21.2% in the first quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company's stock valued at $15,986,000 after buying an additional 24,930 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. bought a new stake in shares of Gilead Sciences during the first quarter worth approximately $11,688,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer owned 595,725 shares of the company's stock, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock valued at $9,390,030. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

GILD stock traded up $0.47 during midday trading on Friday, reaching $114.09. 12,580,487 shares of the company's stock traded hands, compared to its average volume of 5,841,828. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock's 50-day moving average is $114.10 and its 200 day moving average is $110.06. Gilead Sciences, Inc. has a 52-week low of $81.83 and a 52-week high of $121.83. The stock has a market cap of $141.56 billion, a P/E ratio of 22.73, a PEG ratio of 0.77 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the business posted $2.01 EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's dividend payout ratio is 62.95%.

Analyst Ratings Changes

Several brokerages recently issued reports on GILD. Royal Bank Of Canada boosted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.